INTRODUCTION
============

Modern drug discovery is primarily focused on the search or design of drug-like molecules, which selectively interact and modulate the activity of one or a few selected therapeutic targets ([@gkr797-B1]). One challenge in drug development is to choose and explore promising targets from a growing number of potential targets ([@gkr797-B4]). Target selection and validation are important not only for achieving therapeutic efficacy but also for increasing drug development odds, given that few innovative targets have made it to the approved list each year \[12 innovative targets in 1994--2005 ([@gkr797-B5]) and 10 new human targets in 2006--2010 ([@gkr797-B6]) for small molecule drugs\]. Apart from target selection and validation, drug discovery efforts can be facilitated by enhanced knowledge of bioactive molecular scaffolds ([@gkr797-B7],[@gkr797-B8]), structure--activity relationships ([@gkr797-B9]), multi-target agents ([@gkr797-B10],[@gkr797-B11]) and synergistic drug combinations ([@gkr797-B12]) against selected target or multiple targets, and information about the sources of drug leads such as the species origins of natural product-derived drugs ([@gkr797-B13]).

Internet resources such as Therapeutic Target Database (TTD) ([@gkr797-B14],[@gkr797-B15]) and DrugBank ([@gkr797-B16]) provide comprehensive information about the targets and drugs in different development and clinical stages, which are highly useful for facilitating focused drug discovery efforts and pharmaceutical investigations against the most relevant and proven targets ([@gkr797-B17]). In addition to the update of these databases by expanded target and drug data contents, the usefulness of these databases for facilitating drug discovery efforts can be further enhanced by adding additional information and knowledge derived from the target and drug discovery processes. Therefore, we updated TTD by both significantly expanding the target and drug data and adding new information about target validation, quantitative structure--activity relationship (QSAR) models of a variety of molecular scaffolds active against selected targets and specific types of drugs (multi-target drugs and natural product-derived drugs) and drug combinations (synergistic, additive, antagonistic, potentiative and reductive combinations).

The significantly expanded target and drug data cover 364 successful, 286 clinical trial, 44 discontinued clinical trial and 1331 research targets, and 1540 approved, 1423 clinical trial, 345 discontinued clinical trial, 165 pre-clinical and 14 853 experimental drugs linked to their primary targets (14 170 small molecule and 652 antisense drugs with available structure and sequence data) ([Table 1](#gkr797-T1){ref-type="table"}). These are compared to 348 successful, 249 clinical trial, 43 discontinued clinical trial and 1254 research targets, and 1514 approved, 1212 clinical trial and 2302 experimental drugs in our last update ([@gkr797-B15]). To facilitate the access of clinical trial information of the clinical trial drugs, cross-links to the relevant page in ClinicalTrials.gov database are provided for 770 clinical trial drugs. The newly added target validation data includes the experimentally measured potency of 11 810 drugs against 915 targets, the observed potency or effects of 497 drugs against disease models (cell lines, *ex vivo*, *in vivo* models) linked to 393 targets, and the observed effects of target knockout, knockdown or genetic variations for 307 targets ([Table 2](#gkr797-T2){ref-type="table"}). The QSAR data consists of 841 QSAR models for active compounds of 228 chemical types against 121 targets ([Table 2](#gkr797-T2){ref-type="table"}). Table 1.Statistics of drug targets, drugs and structure and sequence data in TTD databaseData Category2012 update2010 updateStatistics of drug targets    Number of all targets20251894    Number of successful targets364348    Number of clinical trial targets286249    Number of discontinued targets4443    Number of research targets13311254Statistics of drugs    Number of all drugs17 8165028    Number of approved drugs15401514    Number of clinical trial drugs14231212    Number of discontinued drugs345274    Number of pre-clinical drugs165142    Number of experimental drugs14 8532302Statistics of drugs with available structure or sequence data    Number of small molecular drugs with available structure14 1703382    Number of antisense drugs with available sequence data652649 Table 2.Summary and statistics of newly added data in 2012 version of TTDData CategoryNumber of InformationTarget validation data    Experimentally measured potency of drugs against targets        Number of drugs11 810        Number of targets915    Drug potency against disease model (cell-lines, *ex vivo*, *in vivo* models)            Number of drugs497            Number of targets393    The observed effects of target knockout, knockdown or genetic variations            Number of targets307QSAR models    Number of QSAR models841    Number of Chemical types228    Number of targets121Structure and potency information of multi-target agents against target pairs        Number of multi-target agents3681        Number of target pairs108Drug combination data    Pharmacodynamically synergistic drug combinations        Number of drug combinations due to anti-counteractive actions22        Number of drug combinations due to complementary actions30        Number of drug combinations due to facilitating actions20    Number of pharmacodynamically additive drug combinations14    Number of pharmacodynamically antagonistic drug combinations4    Number of pharmacokinetically potentiative drug combinations19    Number of pharmacokinetically reductive drug combinations7Natural product-derived drugs and their species origins    Number of natural product-derived approved drugs939    Number of natural product-derived clinical trial drugs369    Number of natural product-derived pre-clinical drugs119

Moreover, we added the data partly derived from our previous studies of multi-target drugs ([@gkr797-B20],[@gkr797-B21]), drug combinations ([@gkr797-B12]) and natural product derived drugs ([@gkr797-B13]) ([Table 2](#gkr797-T2){ref-type="table"}). The multi-target drug data is composed of 3681 multi-target agents active against 108 target pairs together with their potencies against the target pairs. The drug combination data includes 72, 14 and 4 pharmacodynamically synergistic, additive and antagonist combinations, and 19 and 7 pharmacokinetically potentiative and reductive combinations together with their mode of actions and combination mechanisms. The natural product-derived drug data includes the drug names and their species origins and species families for 939 approved, 369 clinical-trial and 119 pre-clinical drugs.

NEW TARGET AND DRUG DATA COLLECTION
===================================

Additional target and drug data, including the approved, clinical trial and experimental drugs and their primary targets, were collected by using the same methods described in our previous publications ([@gkr797-B14],[@gkr797-B15]). In particular, all TTD targets are primary targets (i.e. efficacy targets) directly responsible for the claimed therapeutic efficacies (in drug approval, clinical trial or investigations) of the corresponding drugs as confirmed by biochemical assay and strong cell based and/or *in vivo* evidence linking the target to drug ([@gkr797-B15],[@gkr797-B17],[@gkr797-B22]). The status of approved drugs and clinical trial drugs is up-to-date as of December 2010. The discontinued clinical trial drugs are based on the report from US National Institutes of Health (NIH, <http://clinicaltrials.gov/>). The discontinued clinical trial targets are those clinical trial targets that no longer have an active clinical trial drug at the end of 2010. Pre-clinical drugs are drug candidates that have passed discovery stages and started such pre-clinical studies as safety, PK/ADME, active pharmaceutical ingredient preparation and formulation ([@gkr797-B23]). The newly added experimental drugs were selected based on a potency cut-off value of ≤20 µM against their targets.

TARGET VALIDATION DATA
======================

Target validation has been routinely performed to demonstrate the functional role of the potential target in disease phenotype and the ability of drug-like molecules to modulate the activities of the target to achieve therapeutic efficacies ([@gkr797-B24],[@gkr797-B25]). Target validation normally requires the determination that the target is expressed in the disease-relevant cells/tissues, it can be directly modulated by a drug or drug-like molecule with adequate potency in biochemical assay, and that target modulation in cell and/or animal models ameliorates the relevant disease phenotype ([@gkr797-B24],[@gkr797-B26]). *In vivo* target validation has been conducted mostly in knockout mice, transgenetic *in vivo* models, and also in RNA interference, antibody and antisense treated *in vivo* models ([@gkr797-B26],[@gkr797-B27]). We therefore searched the PubMed database ([@gkr797-B28]) to collect from literature three types of target validation data: experimentally determined potency of drugs against their primary target or targets, observed potency or effects of drugs against disease models (cell lines, *ex vivo*, *in vivo* models) linked to their primary target or targets, and the observed effects of target knockout, knockdown, transgenetic, RNA interference, antibody or antisense-treated *in vivo* models. Target validation data can be retrieved by clicking the 'Target Validation' field in the TTD home page, which lead to the TTD target validation information page wherein a user can select the relevant data for a particular target from the target name list ([Figure 1](#gkr797-F1){ref-type="fig"}). Figure 1.The target validation information page of TTD.

QUANTITATIVE STRUCTURE--ACTIVITY RELATIONSHIP MODELS AGAINST SPECIFIC TARGET
============================================================================

QSAR models for active compounds against many different targets have been developed and explored for drug lead discovery and optimization ([@gkr797-B9],[@gkr797-B29]). These models elucidate the chemical characteristics favorable to the modulation of the activity of specific target at sufficient potency by establishing quantitative correlations between molecular properties and biological activities (e.g. 50% inhibition concentration or binding affinities) ([@gkr797-B30]). In drug lead optimization projects, QSAR models against specific target can be recursively developed and used for guiding the design or search of more potent compounds or compounds with more desired drug-like properties as the new activity or drug-like property data from newly synthesized compounds become available ([@gkr797-B9],[@gkr797-B29]). Therefore, knowledge of developed QSAR models for different molecular scaffolds active against different targets is highly useful for facilitating further drug development and lead optimization efforts. In addition to the QSAR models, we have collected in our previous analysis of QSAR models of bioactive compounds ([@gkr797-B31]), we searched PubMed database ([@gkr797-B28]) to collect 309 papers that describe 841 ligand-based QSAR models for active compounds of 228 chemical types against 121 targets. While there are also a high number of papers describing receptor-based QSAR models, these models were not included in TTD because they are not easily displayed in explicit form in a database setting without obtaining copyrights from the relevant journals. The included QSAR models can be accessed by clicking the 'QSAR Models' field in the TTD home page, which lead to the TTD QSAR model page wherein a user can select the relevant model for a particular chemical class against a specific target either from the target name list or the chemical type list ([Figure 2](#gkr797-F2){ref-type="fig"}). The retrieved QSAR model page ([Figure 3](#gkr797-F3){ref-type="fig"}) contains the information about target and ID, target species, chemical type, compound mode of action, QSAR models, the molecular descriptors in the QSAR models, references and hyperlinks to the molecular descriptor computation web servers MoDeL ([@gkr797-B32]) and e-dragon ([@gkr797-B33]). Figure 2.QSAR model page of TTD. Figure 3.The page of the QSAR models for a particular chemical class against a specific target in TTD.

MULTI-TARGET AGENTS
===================

Therapeutic agents directed at an individual target frequently show reduced efficacies, undesired safety profiles and drug resistances due to network robustness, redundancy, cross-talk, compensatory and neutralizing actions, anti-target and counter-target activities ([@gkr797-B34]). Multi-target agents directed at selected multiple targets have been increasingly explored for enhanced therapeutic efficacies, improved safety profiles and reduced resistance activities by simultaneously modulating the activity of a primary target and the counteractive elements ([@gkr797-B3],[@gkr797-B37],[@gkr797-B38]). In addition to the multi-target agents we have collected in our previous studies of multi-target drugs ([@gkr797-B20],[@gkr797-B21]), we further searched PubMed ([@gkr797-B28]) using such keywords as 'multi-target', 'dual target' and 'dual inhibitor'. Multi-target agent against a target pair refers to a compound active against both targets at potency values of ≤20 µM regardless of their possible activities against other targets. The 3D structures of these multi-target agents were generated by using CORINA ([@gkr797-B39]) from the 2D structures manually drawn based on the literature provided structures or the structures found in such chemical databases as BindingDB ([@gkr797-B40]), ChEMBL ([@gkr797-B41]) and PubChem ([@gkr797-B28]). These multi-target agents can be retrieved by clicking the 'Multi-Target Agents' field in the TTD home page, which lead to the TTD multi-target agents page wherein a user can download the multi-target agents against a specific target pair from the target pair list ([Figure 4](#gkr797-F4){ref-type="fig"}). Figure 4.Multi-target agents page of TTD.

DRUG COMBINATIONS
=================

Apart from multi-target agents, drug combinations have also been extensively explored for enhanced therapeutic efficacies, improved safety profiles and reduced resistance activities ([@gkr797-B12],[@gkr797-B38],[@gkr797-B42]). When two drugs produce the same broad therapeutic effect, their combination collectively produces the same effects of various magnitudes in contrast to the summed response of the individual drugs. A drug combination is pharmacodynamically synergistic, additive or antagonistic if the effect is greater than, equal to or less than the summed response of the individual drugs ([@gkr797-B43]). Drug combinations may also produce pharmacokinetically potentiative or reductive effects such that the therapeutic activity of one drug is enhanced or reduced by another drug via regulation of the first drug\'s ADME ([@gkr797-B43]). In our earlier studies of drug combinations ([@gkr797-B12]), we have searched PubMed ([@gkr797-B28]) to select those literature-reported drug combinations evaluated by rigorous combination analysis methods and with known molecular mechanism of combination retrievable from PubMed by using combinations of the keywords 'drug combination', 'drug interaction', 'multi-drug', 'additive', 'antagonism', 'antagonistic', 'infra-additive', 'potentiated', 'potentiative', 'potentiation', 'reductive', 'supra-additive', 'synergism', 'synergistic' and 'synergy'.

All major classes of drug combinations can be further divided into groups of specific action types ([@gkr797-B12]). Pharmacodynamically synergistic drug combinations can be divided into three groups: each one with anti-counteractive, complementary and facilitating actions, respectively. Anti-counteractive actions reduce network\'s counteractive activities against a drug\'s therapeutic effect. Complementary actions positively regulate a target or process by interactions with multiple target/pathway sites, different target subtypes and states, and competing mechanisms ([@gkr797-B3]). Facilitating actions are secondary actions of one drug in enhancing the activity or level of another drug. Pharmacodynamically additive drug combinations can be divided into two groups, one with equivalent or overlapping actions, and the other with independent actions of the drugs involved. Pharmacodynamically antagonistic drug combinations can also be divided into two groups, one with mutually interfering actions at the same target, another with mutually counter-active actions at different targets of related pathways that regulate the same target. Pharmacokinetically potentiative drug combinations can be divided into three groups, each one with positive modulation of drug transport or permeation, drug distribution or localization and drug metabolism, respectively. Pharmacokinetically reductive drug combinations can be divided into three groups, each one with negative modulation of drug transport or permeation, drug distribution or localization and drug metabolism, respectively. These drug combinations and their combination mechanisms can be accessed by clicking the 'Drug Combinations' field in the TTD home page, which lead to the TTD drug combinations page wherein a user can download the relevant drug combination data from the drug combination type list ([Figure 5](#gkr797-F5){ref-type="fig"}). Figure 5.Drug combination page of TTD.

NATURAL PRODUCT-DERIVED DRUGS
=============================

Many of the approved and clinical trial drugs are derived from natural products ([@gkr797-B44],[@gkr797-B45]). Although drug discovery focus has been shifted from natural products to synthetic chemicals, natural product-derived drugs still constitute a substantial percentage of recently approved drugs (26% of the 46 FDA approved new molecular entities in 2009--2010 are natural product derived) ([@gkr797-B13]). There is a renewed interest in natural products as sources for drug discovery ([@gkr797-B46]). Knowledge of the natural sources of drugs, the species origins of the natural product-derived approved, clinical trial and pre-clinical drugs, are highly useful for facilitating the search and development of new drug leads. In our earlier analysis of the species origins of natural product-derived drugs, we have collected the species origins and species families of natural product-derived approved, clinical trial and pre-clinical drugs ([@gkr797-B13]).

The species-origins of these drugs have been identified as follows. First the literature-reported approved drugs ([@gkr797-B44]), clinical trial ([@gkr797-B45],[@gkr797-B47]) and pre-clinical ([@gkr797-B13]) drugs of natural origin were evaluated with respect to the drugs in our TTD database ([@gkr797-B15]) to check their current approval or clinical trial status. Then the species-origin of every drug was searched from books, review and regular articles by using combinations of such keywords as drug name and alternative names, species, natural product and nature. The species-origin of a drug is confirmed if it is specifically mentioned that it 'originates from', 'derived from', 'isolated from' or 'comes from' a species or species-group (e.g. genus or family). For drugs of semi-synthetic derivatives, mimics and peptidomimetics, their parent natural product leads were first searched followed by the search of host species as described above. The corresponding species-families of the host-species of these drugs as well as all the known species-families in the nature are from the NCBI taxonomy database ([@gkr797-B28]). These natural product-derived drugs and their species origins and families can be retrieved by clicking the 'Nature-Derived Drugs' field in the TTD home page, which lead to the TTD natural product-derived drugs page wherein a user can download the relevant data from the drug status list ([Figure 6](#gkr797-F6){ref-type="fig"}). Figure 6.Natural product-derived drugs page of TTD.

REMARKS
=======

A goal in updating TTD is to make it into a more useful target and drug discovery resource in complement to other related databases. Continuous efforts will be made to provide the latest and comprehensive information about the primary (efficacy) targets of approved, clinical trial, pre-clinical and experimental drugs and other relevant data for these drugs. Intensive efforts in drug and target discovery have led to and will continue to enable the generation of new information, knowledge and models from existing targets ([@gkr797-B18]), drugs ([@gkr797-B9],[@gkr797-B29],[@gkr797-B48],[@gkr797-B49]), multi-target drugs ([@gkr797-B20]) and drug combinations ([@gkr797-B12],[@gkr797-B38],[@gkr797-B42]). Drug discovery efforts have benefited and are continuing to be benefited from the exploration of multiple lead sources including synthetic chemicals ([@gkr797-B1]), biologics ([@gkr797-B50]) and natural products ([@gkr797-B13],[@gkr797-B44],[@gkr797-B45]). Inclusion of these information, knowledge and models into TTD and other databases will further enable these databases to better serve the drug discovery and research communities in their efforts for discovering new targets and new drugs from different sources.
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